Summary
A new doxycycline formulation consisting of enteric-coated doxycycline hyclate pellets in capsules is aimed at reducing gastrointestinal adverse reactions related to doxycycline therapy. In this randomised, double-blind, 3-way crossover study, adverse reactions caused by short term treatment with enteric-coated doxycycline hyclate pellets in capsules were compared with placebo and doxycycline monohydrate tablets. The latter are generally considered to be better tolerated than older formulations of doxycycline hyclate. 111 healthy volunteers completed the study. They were given 150mg of doxycycline once daily over 3 consecutive days with a washout of 4 to 10 days between the study periods. The medication was administered after an overnight fast (10 hours) with 200ml of tap water. An upright position was maintained for 1 hour and no food was allowed for 2 hours after drug administration. Participants recorded adverse reactions daily. Adverse reactions were reported by 66% of the subjects during treatment with doxycycline monohydrate, while 43% reported adverse reactions during treatment with enteric-coated doxycycline hyclate and 30% during placebo. Compared with the 2 other groups, doxycycline monohydrate caused significantly more adverse reactions in general, and abdominal pain, nausea and vomiting in particular. It is concluded that enteric-coated doxycycline hyclate pellets in capsules have significantly better gastrointestinal tolerability compared with doxycycline monohydrate.
Similar content being viewed by others
References
Cunha BA, Sibley CM, Ristucca AM. Doxycycline. Ther Drug Monit 1982; 4: 115–35
Doxycycline (hydrochloride). In: Dollery Colin Sir, editor. Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1991: D225–D228
Bryant SG, Fisher S, Kluge RM. Increased frequency of doxycycline side-effects, Pharmacother 1987; 7: 125–9
Beltran RR, Herrero JIH. Evaluation of ciprofloxacin and doxycycline in the treatment of mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 1992; 11: 427–31
De Vlieger A, Druart M, Puttemans M. Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. Diagn Microbiol Infect Dis 1992; 15: 123S–7
Schouwenburg van J, Bruyn de O, Fourie E, et al. A randomized, comparative study of the efficacy and tolerance of roxithromycin and doxycycline in the treatment of women with positive endocervical cultures for chlamydia trachomatis and mycoplasma spp. in an in vitro fertilization program. Diagn Microbiol Infect Dis 1992; 15: 129S–131S
Williams DB, O’Reilly WJ, Boehm G, et al. Absorption of doxycycline from a controlled release pellet formulation: The influence of food on bioavailability. Biopharm Drug Disp 1990; 11: 93–105
Berger RS. A double-blind, multiple dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx® and Vibramycin®. J Clin Pharmacol 1988; 28: 367–70
Story JM, McCloud PI, Boehm G. Doxycycline tolerance study. Incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx® vs Vibramycin®). Eur J Clin Pharmacol 1991; 40: 419–21
Carlborg B, Farmer JC. Esophageal corrosion tests with doxycycline monohydrate tablets. Curr Ther Res 1983; 34: 110–6
Lanza FL. Esophageal ulceration produced by doxycycline. Curr Ther Res 1988; 44: 475–84
Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications, 1987, 10–3
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03257462.
Rights and permissions
About this article
Cite this article
Järvinen, A., Nykänen, S., Paasiniemi, L. et al. Enteric Coating Reduces Upper Gastrointestinal Adverse Reactions to Doxycycline. Clin. Drug Invest. 10, 323–327 (1995). https://doi.org/10.2165/00044011-199510060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199510060-00002